CytomX appoints Alan Ashworth, Ph.D., FRS to Board of Directors as Class III director

CytomX Therapeutics, Inc.

Appointment effective Sept 29, 2021, filling a vacancy; term expires at 2024 annual meeting.
Standard non-employee director compensation, including option for 40,000 shares vesting monthly over 3 years.
Company will enter into a standard indemnification agreement with Dr. Ashworth.
No transactions exceeding $120,000 involving Dr. Ashworth; no arrangements for appointment.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Alan Ashworth

Class III director

CTMX · CytomX Therapeutics, Inc.

Effective: 2021-09-29
Filed: October 4, 2021, 7:59 PM ET

On September 29, 2021, Alan Ashworth, Ph.D., FRS was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective September 29, 2021, as a Class III director, with an initial term expiring at the Company’s 2024 annual meeting of stockholders, filling a vacancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Alan Ashworth was appointed as Class III director at CytomX Therapeutics, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

On September 29, 2021, Alan Ashworth, Ph.D., FRS was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective September 29, 2021, as a Class III director, with an initial term expiring at the Company’s 2024 annual meeting of stockholders, filling a vacancy.

View on SEC.gov

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-290428

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.